Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers
A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 to Treat Chronic Nonhealing Foot Ulcers in Diabetic Patients With Concomitant Peripheral Arterial Disease (PAD)
Sponsor: Helixmith Co., Ltd.
Terminated
Low enrollment
Other Foot Ulcer, Diabetic trials with similar outcome
A PHASE3 clinical study on Foot Ulcer, Diabetic, this trial is terminated or withdrawn. The trial is conducted by Helixmith Co., Ltd. and has accumulated 19 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
19 versions recorded-
Nov 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Terminated PHASE3
-
Apr 2025 — Sep 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — Apr 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
▶ Show 14 earlier versions
-
Mar 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Terminated PHASE3
Status: Unknown Status → Terminated
-
Oct 2021 — Feb 2023 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE3
-
Sep 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2019 — Sep 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Jun 2019 [monthly]
Recruiting PHASE3
-
Aug 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Nov 2017 — Feb 2018 [monthly]
Recruiting PHASE3
-
Aug 2017 — Nov 2017 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Aug 2017 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Helixmith Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .